[1] Korppi M,Heiskanen-Kosma T,Kleemola M.Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae:Serological results of a prospective, population-based study in primary health care[J].Respirology,2004,9(1):109-114.
[2] Wang K,Gill P,Perera R,et al.Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia[J].Cochrane Database Syst Rev,2012,10:CD009175.
[3] 徐莉燕. 儿童社区获得性肺炎578例回顾性分析[D].郑州:郑州大学,2014.
[4] 肖红丽,刁宗礼,马素霞,等.肺炎支原体肺炎的肺外表现[J].中国医刊,2009,44(11):14-16.
[5] 赵胃胃,赵华,王鑫.儿童肺炎支原体肺炎发病机制的研究进展[J].中华临床医师杂志(电子版),2015,9(20):3759-3763.
[6] Bebear C,Pereyre S,Peuchant O.Mycoplasma pneumoniae: susceptibility and resistance to antibiotics[J].Future Microbiol, 2011,6(4):423-431.
[7] Bradley JS,Byington CL,Shah SS,et al.The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America[J].Clinical Infectious Diseases,2011,53(7): E25-E76.
[8] Gardiner SJ,Gavranich JB,Chang AB.Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children[J].Cochrane Database Syst Rev,2015,1:CD004875.
[9] 刘瀚旻,陆权,洪建国,等.儿童肺炎支原体感染治疗的系统评价[J].中华儿科杂志,2016,54(2):111-118.
[10] Galli L,Montagnani C,Chiappini E,et al.Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance[J].Acta Paediatr,2013,102(465):25-33.
[11] Zhao F,Lv M,Tao X,et al.Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing,China[J].Antimicrob Agents Chemother, 2012,56(2):1108-1109.
[12] Paukner S,Riedl R.Pleuromutilins:Potent Drugs for Resistant Bugs-Mode of Action and Resistance[J].Cold Spring Harb Perspect Med,2017,7(1):a027110.
[13] Sader HS,Paukner S,Ivezic-Schoenfeld Z,et al.Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory
[14] tract infections (CARTIs)[J].J Antimicrob Chemother,2012,67(5): 1170-1175.
[15] Waites KB,Crabb DM,Duffy LB,et al.In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States,Europe,and China[J].Antimicrob Agents Chemother,2017,61(2):e02008.
[16] Heilmann C,Jensen L,Jensen JS,et al.Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic[J].J Infect,2001,43(4):234-238.
[17] Youn YS,Lee SC,Rhim JW,et al.Early Additional Immune-Modulatorsfor Mycoplasma pneumoniae Pneumonia in Children:An Observation Study[J].Infect Chemother,2014,46(4):239-247.
[18] 高斐,李海燕.治疗儿童肺炎支原体肺炎免疫损伤的研究进展[J].世界最新医学信息文摘,2017,17(9):63-64.
[19] 戴春勤,戴望舒.阿奇霉素联合头孢类抗生素、激素及免疫球蛋白治疗儿童重症支原体肺炎临床疗效[J].齐齐哈尔医学院学报,2015,36(13):1909-1910.
[20] 刘金荣,赵顺英.难治性肺炎支原体肺炎判断与药物治疗[J].中国实用儿科杂志,2013,28(12):881-883.
[21] 吴正春.布地奈德雾化吸入辅助治疗儿童肺炎支原体肺炎的疗效研究[J].世界临床医学,2017,11(12):108,111.
[22] 闫威. 布地奈德雾化吸入对肺炎支原体肺炎患儿的临床疗效[J].牡丹江医学院学报,2016,37(6):51-52.
[23] 胡贵珍,蒋英,申洁琼.小儿支原体肺炎血锌含量分析及应用补锌制剂对疾病治疗的影响[J].黑龙江医学,2016,40(1):28-29.
[24] 赵嘉丽,王有鹏.小儿支原体肺炎的中医内治概述[J].新中医,2015,47(7):3-5.
[25] 叶佐荣,张绍文.银翘芩百汤联合阿奇霉素治疗小儿支原体肺炎临床观察[J].新中医,2017,49(2):106-108.
[26] 邱林军. 抗支清肺汤联合阿奇霉素治疗小儿支原体肺炎的疗效分析[J].中国中医药科技,2017,24(1):68-69.
[27] 过毅,葛小丽,吴莹莹,等.肺炎支原体耐药机制研究进展[J].中华医院感染学杂志,2016,26(20):4782-4784. |
